BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Omeros Corporation (OMER) Files Universal Shelf Registration Statement to Replace Expiring Universal Shelf Registration Statement


10/18/2013 9:47:13 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SEATTLE, Oct. 17, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has filed a replacement universal shelf registration statement (the "2013 Registration Statement") with the Securities and Exchange Commission (the "SEC"). The 2013 Registration Statement was filed as routine course of business due to the impending expiration of the company's existing universal shelf registration statement (the "2010 Registration Statement") that, under SEC rules, would have expired on Friday, October 18, 2013. Pursuant to SEC rules, the expiration date of the 2010 Registration Statement has been extended until the earlier of the effective date of the 2013 Registration Statement or April 16, 2014. Upon effectiveness, the company may use the 2013 Registration Statement to offer and sell common and preferred stock, debt securities and other securities having an aggregate offering amount of no more than $100 million, which is the amount that was registered under the 2010 Registration Statement. The 2013 Registration Statement, once it becomes effective, will continue to provide the company with flexibility to access the public capital markets in response to financing and business opportunities that may arise from time to time over its expected three-year term. No sales will occur under the 2013 Registration Statement prior to the time it becomes effective.

This press release is neither an offer to sell nor the solicitation of an offer to buy any securities and shall not constitute an offer or solicitation in any jurisdiction where such offer or solicitation is unlawful.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system.

Contact:
Jennifer Cook Williams
Cook Williams Communications, Inc.
Investor and Media Relations
360.668.3701
jennifer@cwcomm.org

SOURCE Omeros Corporation



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES